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Introduction {#s1}
============

Sleep-disordered breathing (SDB) is characterized by repeated apnea and hypopnea events [@pone.0111412-Peppard1]. SDB contributes to acute pathophysiological consequences, such as hypoxemia/hypercapnia, fragmented sleep, and exaggerated fluctuations in heart rhythm, blood pressure, and intrathoracic pressure, that can develop into long-term sequelae such as hypertension and other cardiovascular morbidities [@pone.0111412-Peppard1]--[@pone.0111412-Shamsuzzaman1]. The most prevalent SDB, affecting 14% and 5% of American men and women, respectively, is obstructive sleep apnea (OSA) [@pone.0111412-Peppard1]. Standard treatment for OSA is to pneumatically splint the upper airway using continuous positive airway pressure (CPAP). CPAP is extremely efficacious when used properly; however, CPAP is poorly tolerated [@pone.0111412-Weaver1]. Other mechanical treatments exist, but there are no approved pharmacologic treatments for OSA [@pone.0111412-Mason1], and efforts to develop such treatments have been hampered by incomplete knowledge of the relevant state-dependent peripheral and central neural mechanisms controlling upper airway muscles.

The vagus nerves are integral peripheral components in respiratory control, carrying important information from the lungs that contributes to reflex responses regulating: tidal volume, respiratory frequency, augmented breaths and bronchoconstriction [@pone.0111412-Kaczynska1]. The nodose ganglia of the vagus nerves contain receptors for amino acids, monoamines, neuropeptides, and other neurochemicals that, when activated, can modify vagal afferent activity [@pone.0111412-Zhuo1]. Decreasing afferent vagal nerve activity by pharmacological intervention increases upper airway activity [@pone.0111412-Fenik1], and ameliorates SDB in rats [@pone.0111412-Radulovacki1] and bulldogs [@pone.0111412-Veasey1]. Conversely, increasing vagal nerve activity by intraperitoneal (IP) injection of serotonin (5-HT) increases sleep apnea frequency in conscious rats [@pone.0111412-Carley1]. Similarly, humans with vagus nerve stimulators implanted for refractory epilepsy have increased apnea-hypopnea index during sleep [@pone.0111412-Parhizgar1].

A recent and novel approach to alleviate OSA is the administration of dronabinol, a nonselective cannabinoid type 1 (CB~1~) and type 2 (CB~2~) receptor agonist. Systemic administration of dronabinol attenuates spontaneous sleep-related apnea in chronically-instrumented conscious rats [@pone.0111412-Carley2] and in humans with OSA [@pone.0111412-Prasad1]. However, these experiments in chronically-instrumented rats or humans with OSA do not elucidate the mechanisms involved in the amelioration of apnea by dronabinol.

Using a well-established acute rat model of reflex apnea [@pone.0111412-Yoshioka1], dronabinol injected directly into the nodose ganglia modulated vagal afferents by attenuating 5-HT~3~ receptor-mediated apnea and increasing genioglossus muscle activity [@pone.0111412-Calik1]. However, it is unknown if attenuation of apnea occurs via CB~1~ or CB~2~ receptors, or both [@pone.0111412-Darmani1]--[@pone.0111412-Patel1]. The nodose ganglia contain both CB receptors [@pone.0111412-Rohof1], but it is unknown the relative expression levels of these CB receptors on the nodose ganglia. Generally, CB~1~ receptors are more abundant in the nervous system than CB~2~ receptors [@pone.0111412-Onaivi1], and CB~1~ receptor knock-out mice display more apneas compared to wild-type controls [@pone.0111412-Silvani1]. Further complicating the role of cannabimimetics in afferent vagal activity is the observation that cannabimimetics can suppress nerve/neuronal activity via mechanisms independent of cannabinoid (CB) receptors. In cultured nodose ganglion cells activated by 5-HT, anandamide attenuated 5-HT-induced currents independent of G protein coupled signaling [@pone.0111412-Fan1]. Moreover, cannabimimetics like Δ9-tetrahydrocannabinol (Δ9-THC) and anandamide inhibited 5-HT~3~ receptor induced-currents in cultured HEK 293 cells and Xenopus oocytes, cells that lack CB receptors [@pone.0111412-Barann1], [@pone.0111412-Yang1]. These studies suggest that CBs can allosterically modulate ionotropic receptors [@pone.0111412-Pertwee1].

Here, using the acute rat model of reflex apnea, we hypothesized that the attenuation of 5-HT-induced apnea and the increased upper airway tone produced by nodose ganglion dronabinol injection would be reversed by IP pre-treatment with AM251, a CB~1~ antagonist, but not by pre-treatment AM630, a CB~2~ antagonist.

Methods {#s2}
=======

Ethics statement {#s2a}
----------------

All animal studies, procedures, and protocols were approved by the Animal Care Committee of the University of Illinois at Chicago (Protocol no: 11-217).

Animals {#s2b}
-------

Detailed methods have been previously described [@pone.0111412-Calik1]. Thirty-six adult male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN, USA) were housed in pairs, maintained on a 12∶12 hour light:dark cycle at 22±0.5°C, and given *ad libitum* access to food and water.

Acute Experimental Paradigm {#s2c}
---------------------------

Rats were anesthetized (initial injection ketamine:xylazine 100∶10 mg/kg). In a balanced design, rats were given IP injections of 15% dimethyl sulfoxide (DMSO) in PBS (1 ml) with AM251 (0.5 mg/kg, n = 6; or 5 mg/kg, n = 6), or AM630 (0.5 mg/kg, n = 6; or 5 mg/kg, n = 6), or AM251/AM630 (5/5 mg/kg, n = 6). Vehicle control rats (n = 6) were given IP injections of 15% dimethyl sulfoxide (DMSO) in PBS (1 ml). The femoral vein was cannulated for 5-HT infusion to induce reflex apneas, and insulated stranded stainless steel wire electrodes were inserted bilaterally into the genioglossus muscles (1 mm lateral to the midline) to monitor genioglossus electromyogram (EMGgg). A piezoelectric strain gauge (Ambu, Glen Burnie, MD, USA) placed around the abdomen was used to monitor respiratory pattern. During recordings, surgical plane of anesthesia was monitored by toe pinch, and if necessary, rats were re-injected with anesthetic (ketamine:xylazine 100∶5 mg/kg).

Before neck surgery, baseline respiratory patterns and EMGgg were recorded from 2--3 reflex apnea responses to 5-HT hydrochloride. Serotonin concentration was 12.5 µg/kg (MP Biomedicals, Solon, OH, USA) in PBS (pH 7.4; 0.35 ml/kg) administered via the cannulated femoral vein using an infusion pump (63 ml/hr; KD Scientific, Holliston, MA, USA). After baseline recordings, nodose ganglia were exposed and cleared of connective tissue. Reflex apneas were recorded to confirm that nerves/ganglia were not damaged during the surgery (surgery baseline recording). After confirmation that nerves/ganglia were functionally intact, rats received dronabinol (100 µg/5 µl sesame oil per ganglion; Mylan Pharmaceuticals, Morgantown, WV, USA) injections directly into the nodose ganglia, and then 5-HT infusions and recordings were repeated (nodose injection recording). Infusions of 5-HT were performed at intervals greater than 5 minutes to prevent tachyphylaxis [@pone.0111412-Yoshioka1], [@pone.0111412-Calik1], [@pone.0111412-Ginzel1], [@pone.0111412-Nishi1] and to allow for return to baseline of EMG and respiratory pattern.

Data Processing and Statistical Analysis {#s2d}
----------------------------------------

During data acquisition, EMGgg and respiratory signals were amplified (CyberAmp, Sunnyvale, CA, USA), band-pass filtered (10--240 Hz and 1--10 Hz, respectively), digitized at 500 Hz and recorded using SciWorks Experimenter software (DataWave Technologies, Loveland, CO, USA), and saved on a personal computer. To process data, EMGgg signals were rectified and smoothed with a time constant of 100 ms using Spike2 software (Cambridge Electronic Design, Cambridge, England). Tonic EMGgg signals were defined as the nadir of smoothed expiratory genioglossus activity. Phasic EMGgg signals were defined as the peak of smoothed inspiratory genioglossus activity minus tonic EMGgg. Breath durations, and phasic and tonic EMGgg amplitudes were averaged from the five previous breaths before 5-HT infusion. Apnea durations were defined as the longest breath duration within 30 seconds following 5-HT infusion. Since each rat received 2--3 infusions of 5-HT under each condition (Baseline, Surgery Baseline, and Nodose Injection), the EMGgg and respiratory pattern from the 2--3 infusions were averaged together for each condition.

For statistical analysis, SigmaStat version 3.11 (Systat Software, Inc., Chicago, IL, USA) was used. Data (mean ± SEM) were analyzed using two-way repeated measures ANOVA (condition×antagonist treatment) with Tukey's post hoc multiple comparison test. Statistical significance was set at p\<0.05.

Results {#s3}
=======

CB~1~ and CB~2~ Antagonists Reverse Dronabinol's Attenuation of 5-HT-induced Apnea {#s3a}
----------------------------------------------------------------------------------

[Figure 1](#pone-0111412-g001){ref-type="fig"} demonstrates apnea duration ([Fig. 1A](#pone-0111412-g001){ref-type="fig"}) and breath duration ([Fig. 1B](#pone-0111412-g001){ref-type="fig"}) of respiratory pattern recordings from rats pre-treated with AM251, AM630, combined AM251/AM630, and vehicle. There was a significant interaction between the main effects of antagonist treatment and condition on length of 5-HT-induced apnea duration ([Fig. 1A](#pone-0111412-g001){ref-type="fig"}; F~10,\ 60~ = 2.35, p = 0.02). Post hoc analysis revealed that rats with no IP pre-treatment with CB antagonist (vehicle control) had significantly attenuated apneas after local injection of dronabinol (nodose injection recording) compared to baseline (p = 0.03) and surgery baseline recordings (p = 0.04). These data replicate past findings of locally administered dronabinol's capacity to attenuate reflex apnea [@pone.0111412-Calik1]. CB~1~ or CB~2~ receptor antagonist at both concentrations (0.5 or 5 mg/kg), or combined CB~1~/CB~2~ antagonist, pre-treatment reversed dronabinol's attenuation of reflex apnea.

![Apnea and breath durations quantified from acute 5-HT-induced apnea experiments.\
(**A**) Dronabinol (100 µg) injected into the nodose ganglia significantly attenuated apnea duration. Intraperitoneal injection of cannabinoid type 1 (AM2521), or cannabinoid type 2 (AM630), receptor antagonists, or both, reversed dronabinol's apnea attenuation. \*p\<0.05 compared to surgery baseline recording, Tukey's post hoc multiple comparison test. (**B**) Dronabinol injected into the nodose ganglia did not have any effect on breath duration. However, there was a significant (p\<0.05, two-way repeated measures ANOVA) main effect of condition on breath duration; \*p\<0.05, Tukey's post hoc multiple comparison test.](pone.0111412.g001){#pone-0111412-g001}

Similar to past observations [@pone.0111412-Calik1], there was only a main effect of condition on breath duration ([Fig. 1B](#pone-0111412-g001){ref-type="fig"}; F~2,\ 60~ = 2.35, p\<0.01), characterized by a progressive increase in breath duration through the recordings (baseline \< surgery baseline \< nodose injection). Post hoc analysis revealed increases in breath duration from baseline to surgery baseline (p = 0.02), and from surgery baseline to nodose injections (p\<0.01). The increased breath duration was the result of surgery or from the effects of anesthesia.

CB~1~ and CB~2~ Antagonists Did Not Reverse Dronabinol's Increases in Phasic EMGgg.

[Figure 2](#pone-0111412-g002){ref-type="fig"} illustrates data of phasic ([Fig. 2A](#pone-0111412-g002){ref-type="fig"}) and tonic ([Fig. 2B](#pone-0111412-g002){ref-type="fig"}) genioglossus muscle activity from EMGgg recordings from IP pretreated rats with antagonists or vehicle that had dronabinol locally injected into the nodose ganglia. Consistent with past observations [@pone.0111412-Calik1], dronabinol injected in the nodose ganglia increased phasic EMGgg across the conditions ([Fig. 2A](#pone-0111412-g002){ref-type="fig"}; condition main effect: F~2,\ 60~ = 33.4, p\<0.01). Post hoc tests revealed that pre-treatment with CB antagonists failed to attenuate the increase in phasic EMGgg (Baseline \> Surgery Baseline \> Nodose injection, p\<0.01). Interestingly, there also was a main effect of condition on tonic EMG ([Fig. 2B](#pone-0111412-g002){ref-type="fig"}; condition main effect: F~2,\ 60~ = 3.53, p = 0.04) Post hoc tests revealed that nodose injection tonic EMGgg signals were significantly increased compared to baseline EMGgg signals (p = 0.03).

![Phasic (A) and tonic (B) genioglossus electromyogram amplitude (mV) quantified from acute 5-HT-induced apnea experiments.\
There was a significant (p\<0.05, two-way repeated measures ANOVA) main effect of condition on phasic and tonic genioglossus activity; \*p\<0.05, Tukey's post hoc multiple comparison test. EMGgg = genioglossus electromyogram.](pone.0111412.g002){#pone-0111412-g002}

Discussion {#s4}
==========

Poor patient adherence to CPAP for the treatment of OSA underscores the need to develop better treatment options [@pone.0111412-Weaver1]. Combined with increasing prevalence of OSA and its associated comorbidities [@pone.0111412-Peppard1]--[@pone.0111412-Shamsuzzaman1], tolerable and easily applicable treatments for OSA, like pharmacotherapies, must be developed. However, decades of unsuccessful efforts to identify effective drug treatments for OSA [@pone.0111412-Mason1] highlight the need for novel and innovative approaches.

Dronabinol, a non-selective CB agonist, has been shown to decrease sleep apnea in conscious rats [@pone.0111412-Carley2] and in humans with OSA [@pone.0111412-Prasad1]. In an acute rat model of reflex apnea, 5-HT-induced apnea was attenuated or blocked and phasic EMG increased in rats receiving nodose ganglia injections of dronabinol [@pone.0111412-Calik1], suggesting that modulating vagal afferent activity has an important role in respiratory control [@pone.0111412-Kaczynska1]. Here, we show that dronabinol modulates vagal afferents through both CB~1~ and CB~2~ receptors. By blocking these receptors through IP pre-treatment with CB antagonists, we reversed the attenuation of reflex apnea produced by nodose ganglia injections of dronabinol.

The concept of pharmacologically modulating vagal afferent activity to treat sleep apnea has been employed previously. Yoshioka *et al.* first showed that modulation of vagal afferents by antagonism of 5-HT~3~ receptors in acute experiments in rats attenuated reflex apnea [@pone.0111412-Yoshioka1]. This observation was then extended to spontaneous sleep-related apnea by Radulovacki *et al.* who showed in a chronically-instrumented conscious rats that 5-HT~3~ antagonism decreased sleep apnea frequency [@pone.0111412-Radulovacki1]. Fenik and colleagues suggested that peripheral antagonism of 5-HT~3~ receptors on vagus nerves augments inspiratory drive to hypoglossal nerves in anesthetized, paralyzed, and mechanically ventilated rats [@pone.0111412-Fenik1]. These three studies together provided a rationale for testing 5-HT antagonists in a model of obstructive sleep apnea. Indeed, Veasey *et al.* demonstrated that 5-HT~3~ antagonism reduced the respiratory disturbance index during sleep in the English bulldog [@pone.0111412-Veasey1]. In humans, a serotonin antagonist combined with a selective serotonin reuptake inhibitor decreased apnea-hypopnea index during sleep, but the therapeutic window for this effect appears to be narrow [@pone.0111412-Mason1], [@pone.0111412-Prasad2]. Thus, modulating vagal afferent activity to treat sleep apnea has potential if the correct pharmacotherapy can be applied.

CBs have been used to modulate vagal afferent activity via the inhibitory G protein-coupled (G~i/o~) CB~1~ and CB~2~ receptors located on the nodose ganglia [@pone.0111412-Rohof1]. Vagal afferent modulation via CB receptors has been suggested as a treatment not just for sleep apnea [@pone.0111412-Carley2], [@pone.0111412-Prasad1], but also for emesis [@pone.0111412-Darmani1]--[@pone.0111412-Ray1] and for chronic cough [@pone.0111412-Belvisi1], [@pone.0111412-Patel1]. In the vagally-mediated behavior of emesis, CB~1~ receptors are implicated. In contrast, in the vagally-mediated behavior of chronic cough, CB~2~ receptors are involved. We hypothesized that dronabinol's attenuation of reflex apnea occurred via CB~1~ receptors, and not CB~2~ receptors, because CB~1~ receptors are more abundant in the nervous system than CB~2~ receptors [@pone.0111412-Onaivi1]. Moreover, CB~1~ receptor knock-out mice display more sleep apneas than wild-type controls, suggesting CB tone is important in respiratory stability [@pone.0111412-Silvani1]. However, in our study, when either CB receptor subtype was antagonized, or when both were antagonized, by IP pre-treatment, reflex apnea attenuation by local injection of dronabinol was reversed. CB~1~ and CB~2~ receptors are positively coupled to A-type potassium channels [@pone.0111412-Svizenska1], which are expressed on nodose ganglion cells and are known to decrease nodose ganglion/vagus nerve excitability [@pone.0111412-Doan1]--[@pone.0111412-Glazebrook1]. It is possible that activating only one of the two CB receptor subtypes is insufficient to initiate a G~i/o~ cascade that overcomes 5-HT-induced excitability of the vagus nerve. In contrast, activation of either CB~1~ or CB~2~ receptor centrally had an antiemetic effect in brainstem-induced emesis [@pone.0111412-VanSickle1]. The difference in effects of CB antagonism on vagal afferents seen in reflex apnea compared to vagally-mediated emesis [@pone.0111412-Darmani1]--[@pone.0111412-Ray1] or chronic cough [@pone.0111412-Belvisi1], [@pone.0111412-Patel1] could be due to differential receptor expression on A- and/or C-fibers of the vagus nerves/nodose ganglia. In other words, there might be differences in CB receptor expression profiles between the vagally-mediated behaviors of apnea, emesis, and cough. Less than 60% of nodose ganglia cells exhibit CB~1~ expression [@pone.0111412-Burdyga1], and though CB~2~ receptors are located on vagal afferents [@pone.0111412-Rohof1], no studies have been conducted to quantify to CB~2~ receptors expression; however, there is differential expression of other receptor types on cell bodies in the nodose ganglia [@pone.0111412-Zhuo1]. It is possible that the vagal afferents responsible for emesis and chronic cough express only one of the two subtypes of CB receptors, while vagal afferents responsible for sleep apnea express both CB receptor subtypes. Studies to look at CB receptor expression in the nodose ganglia would be of interest.

CBs have been reported to allosterically modulate many different types of ionotropic receptors [@pone.0111412-Pertwee1], including 5-HT receptors on nodose ganglion cells. Anandamide, a cannabimimetic, attenuated 5-HT-induced currents in cultured nodose ganglion cells independent of G protein coupled signaling [@pone.0111412-Fan1]. In cultured HEK 293 cells and Xenopus oocytes, cells that lack CB receptors, Δ9-THC and anandamide inhibited 5-HT-induced currents [@pone.0111412-Barann1], [@pone.0111412-Yang1]. Barann and colleagues also showed that 9-THC reduced 5-HT-induced current in dissociated rat nodose ganglion cells [@pone.0111412-Barann1]. However, no CB receptor antagonists were used in these electrophysiological experiments, so determination of whether the current reduction was attributable to CB receptor dependent or independent mechanisms is unknown. However, in the present work, CB antagonism was sufficient to reverse dronabinol's effect on reflex apnea, arguing against dronabinol acting via CB receptor-independent mechanisms. However, Yang and colleagues showed that allosteric inhibition of the 5-HT~3~ receptor via cannabidiol, a cannabimimetic, is dependent on expression levels 5-HT~3~ receptor [@pone.0111412-Yang1]. It could be that the high expression levels of 5-HT~3~ on nodose ganglion cells [@pone.0111412-Zhuo1] and the dose of dronabinol used to inject into the nodose ganglia is insufficient to allosterically inhibit 5-HT~3~ receptors, thus leaving the activation of CB receptors as the main inhibitory signal of vagal afferents. Patch clamping electrophysiology of nodose ganglion cells using CB receptor antagonisms need to be conducted to resolve this issue.

In contrast to CB antagonism reversing dronabinol's attenuation of reflex apnea, CB antagonism did not reverse dronabinol-induced increases in phasic or tonic genioglossus EMG. Three explanations can account for this observation. The first possibility is that brainstem respiratory control of the hypoglossal motoneurons responsible for genioglossus activity is distinct from that of the phrenic motoneurons responsible for controlling the diaphragm [@pone.0111412-Peever1]--[@pone.0111412-Tadjalli1]. Vagal afferents from pulmonary and upper airway tissues synapse in the nucleus of the solitary tract (NTS) [@pone.0111412-Hermes1], [@pone.0111412-Marchenko1], which is part of the respiratory circuitry including the ponto-medullary pattern generator that projects to the phrenic and hypoglossal motor nuclei [@pone.0111412-Haji1]. Different areas of the NTS stimulated with L-glutamate lead to different patterns of respiratory responses [@pone.0111412-Marchenko1], and CB receptors are located presynaptically on first-order glutamatergic vagal afferent neurons and on second-order GABAergic neurons in NTS [@pone.0111412-Chen1], [@pone.0111412-Khlaifia1]. It is feasible that systemic pre-treatment with CB receptor antagonists can increase genioglossus activity through modulation of first- and/or second-order NTS neurons that project to hypoglossal motoneurons, but does not affect phrenic motoneurons. A second possibility is that antagonism of CB receptors on hypoglossal motoneurons leads to postsynaptic potentiation [@pone.0111412-Mukhtarov1]. It is possible that systemic pre-treatment with CB receptor antagonists can increase genioglossus activity by directly increasing hypoglossal nerve activity. It remains to be seen how central antagonism of CB receptors differentially modulates genioglossus and diaphragmatic activity.

A final possible explanation of the observation that CB antagonism did not reverse dronabinol-induced increases in EMGgg is that vagal afferent neurons that project to circuitry responsible for upper airway activity might not contain CB receptors [@pone.0111412-Burdyga1], and therefore are not affected by CB receptor antagonism. These vagal afferents are then only inhibited or attenuated by allosteric modulation of the 5-HT~3~ receptor [@pone.0111412-Barann1], [@pone.0111412-Yang1]. Fenik and colleagues have shown that antagonizing 5-HT~3~ receptors peripherally with ondansetron increased inspiratory modulation of hypoglossal nerve activity [@pone.0111412-Fenik1]. This could explain the increases in phasic/tonic EMGgg seen in this study.

In summary, we show that CB~1~ and CB~2~ receptor antagonists reversed the suppression of 5-HT-induced apnea by locally-injected dronabinol into the nodose ganglia, but did not reverse increases phasic activation of the genioglossus. These data support the view that systemic dronabinol stabilizes respiratory pattern, in part, by acting via CB~1~ and CB~2~ receptors at the nodose ganglia. These findings underscore the therapeutic potential of dronabinol in the treatment of OSA and implicate participation of both cannabinoid receptors in dronabinol's apnea suppression effect.
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